AZ/MSD’s Lynparza sees positive results in prostate cancer

AstraZeneca and MSD have announced positive phase III results for their PARP inhibitor Lynparza (olaparib) in metastatic castration-resistant prostate cancer (mCRPC).

Bayer aims at J&J and Pfizer with new prostate cancer drug

The FDA has approved Bayer and Orion’s prostate cancer drug darolutamide in the early stages of the disease as it takes on rivals such as Johnson & Johnson.

EMA starts review of Xtandi in hormone-sensitive prostate ca...

EU safety experts begin review of leuprorelin-containing dru...

European safety experts are to begin a review of leuprorelin-containing medicines, commonly used in breast and prostate cancer and as a contraceptive.

AZ/Merck & Co reveal data supporting PARP drug in prostate c...

PARP, or poly (ADP-ribose) polymerase, inhibitors may have an amusing-sounding name but an increasing body of evidence suggest they could be used in a wide range of cancers as long as certa

J&J unveils early-stage prostate cancer data from Erleada at...

Johnson & Johnson is hoping to expand the use of its prostate cancer drug Erleada (apalutamide) in patients with metastatic castration-sensitive prostate cancer (mCSPC) – and new data p